SARS-CoV-2 Spike RBD LlaMABodyTM Bivalent VHH HuIgG2 Fusion Antibody, R&D Systems™

Llama Monoclonal Antibody

Supplier:  R&D Systems LMAB10870SP

Catalog No. LMAB10870SP

Description

Spike RBD Monoclonal antibody specifically detects Spike RBD in SARS-CoV-2 samples. It is validated for Blocking Assay

Specifications

• Antigen: Spike RBD
• Classification: Monoclonal
• Conjugate: Unconjugated
• Formulation: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.
• Host Species: Llama
• Purification Method: Protein A or G purified from cell culture supernatant
• Regulatory Status: RUO
• Reconstitution: Reconstitute at 0.5 mg/mL in sterile PBS.
• Content And Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 6 months, -20 to -70°C under sterile conditions after reconstitution.

• Applications: Blocking Assay
• Clone: L009.2.69H
• Dilution: Blockade of Receptor-ligand Interaction
• Gene Accession No.: YP_009724390.1
• Immunogen: Human embryonic kidney cell HEK293-derived SARS-CoV-2 Spike RBD as immunogen for bivalent Llama VHH-Human IgG2 Fusion Antibody., Arg319-Phe541, Accession # YP_009724390.1
• Quantity: 25 μg
• Primary or Secondary: Primary
• Target Species: SARS-CoV-2
• Form: Purified